Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05711524 · ClinicalTrials.gov registry record · Phase 4
Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
A Phase 4 study of Bleeding and Hypofibrinogenemia, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 4
- Development phase
- 208
- Enrollment target
- 1
- Study location
NCT05711524 is a Phase 4 study of Bleeding and Hypofibrinogenemia that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 208 participants, below the 1,476-participant average among 23 other Bleeding trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05711524, a Phase 4 study of Bleeding and Hypofibrinogenemia, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 208 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this quality improvement study is to compare pathogen-reduced cryoprecipitate with traditional cryoprecipitate in liver transplant and cardiovascular patients. The investigators hypothesize that by having immediate access to a readily available thawed blood product that replaces fibrinogen (the main substrate of a blood clot), early bleeding can be treated before it escalates into uncontrolled hemorrhage, and therefore additional blood products, like platelets, plasma and red blood cells can be avoided. Participants will be given one of the two FDA-approved blood products.
Conditions Studied
Interventions
- BIOLOGICAL Traditional Cryoprecipitate
- BIOLOGICAL Pathogen-Reduced Cryoprecipitate
Study Locations (1)
New York
- New York-Presbyterian Hospital/Weill Cornell Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2025-10-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05711524
The ClinicalTrials.gov registry entry for NCT05711524 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,476-participant average among 23 other Bleeding trials with a reported enrollment target (86% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bleeding appearing as the primary indexed condition, and to 2 interventions - of which Traditional Cryoprecipitate is the first listed.
NCT05711524 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05711524 about?
NCT05711524 is a clinical study titled "Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding". The goal of this quality improvement study is to compare pathogen-reduced cryoprecipitate with traditional cryoprecipitate in liver transplant and cardiovascular patients. The investigators hypothesize that by having immediate access to a readily available thawed blood product that replaces fibrinog...
What is the current status of trial NCT05711524?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 208 participants. The study started on 2023-04-01. Estimated completion is 2025-10-03.
What conditions does trial NCT05711524 study?
This clinical trial studies the following conditions: Bleeding, Hypofibrinogenemia.
What interventions are being tested in trial NCT05711524?
The interventions under investigation include: Traditional Cryoprecipitate (BIOLOGICAL), Pathogen-Reduced Cryoprecipitate (BIOLOGICAL).
Who is sponsoring clinical trial NCT05711524?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05711524 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bleeding
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device
RECRUITING · Phase 4
-
Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users
COMPLETED · Phase 4
-
PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding
COMPLETED · Phase 4
-
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
RECRUITING · Phase 2
-
The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia
RECRUITING
-
Quantra Point-of-Care Hemostasis Monitoring
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.